Skip to main content
. 2017 May 2;69(17):2134–2145. doi: 10.1016/j.jacc.2017.02.046

Table 1.

Demographic and Genotype-Phenotype Correlations of the SADS Cohort

SADS
(n = 302)
SADS and Negative Genetic Testing
(n = 262)
SADS and Positive Genetic Testing
(n = 40)
SADS Without Positive Genetic Testing for
a RYR2 Variant
(n = 285)
SADS and Positive Genetic Testing for a RYR2 Variant
(n = 17)
p Value
Age at death, yrs 24 (17–33) 25 (18–33) 20 (11–32) 25 (18–34) 13 (8–18) 0.0004
Male 197/302 (65) 172/262 (66) 25/40 (62) 183/285 (64) 14/17 (82) 0.1918
Circumstances of death
 Exercise and extreme emotion 30/262 (11) 20/228 (9) 10/34 (29) 21/245 (9) 9/17 (53) <0.0001
 Sleep and rest 188/262 (72) 170/228 (75) 18/34 (53) 183/245 (75) 5/17 (29) 0.0002
 Light activity 44/262 (17) 38/228 (17) 6/34 (18) 41/245 (17) 3/17 (18) 1.0000
Symptoms before death
 Syncope and/or seizures 50/268 (18) 40/235 (17) 10/33 (30) 43/253 (17) 7/15 (47) 0.0101
 Other§ 18/268 (7) 16/235 (7) 2/33 (6) 17/253 (7) 1/15 (7) 1.0000
 None 200/268 (75) 179/235 (76) 21/33 (64) 193/253 (76) 7/15 (47) 0.0269
Family history of SCD <50 yrs of age 19/269 (7) 12/233 (5) 7/36 (19) 16/254 (6) 3/15 (20) 0.0791

Values are median (interquartile range) or n/N (%).

ACMG = American College of Medical Genetics; SADS = sudden arrhythmic death syndrome; SCD = sudden cardiac death.

Positive outcome was defined as a pathogenic or likely pathogenic variant per the ACMG guidelines (12).

p values refer to the following comparison: positive genetic testing RYR2 (n = 17) versus no positive RYR2 test (n = 285).

Note missing data for these parameters and that percentages are based on nonmissing data.

§

Includes palpitations, shortness of breath, and chest pain.